Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies

Bibliography

• Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32s-40s
   PubMed Web of Science ®Google Scholar
• Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7(Suppl 4):2-8
   PubMed Web of Science ®Google Scholar
• Wells A. Molecules in focus: EGF receptor. Int J Biochem Cell Biol 1999;31:637-43
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99
   PubMed Web of Science ®Google Scholar
• Erbitux package insert. March 2006. ImClone Systems Incorporated, New York, NY 10014, USA. and Bristol-Myers Squibb Co; Princeton, NY 08543, USA
   Google Scholar
• Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 2007;18:7-15
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;22:5235-41
   Google Scholar
• Vectibix (panitumumab) prescribing information. (v3, revOctober 2007) Amgen, Inc.: Thousand Oaks, CA. Available from: http://www.vectibix.com/pdfs/misc/vectibix pi.pdf [Accessed 10 March 2008]
   Google Scholar
• Groenestege WM, Thebault S, Van Der Wijst J, Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007;117:2260-7
   PubMed Web of Science ®Google Scholar
• Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med 1997;127:531-7
   PubMed Web of Science ®Google Scholar
• Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_ 30-992.pdf
   Google Scholar
• Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
   PubMed Web of Science ®Google Scholar
• Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(14):2311-19
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Rodenburg CJ, A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19(4):734-8
   PubMed Web of Science ®Google Scholar
• Butts CA, Bodkin D, Middleman EL, Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007;25(36):5777-84; Erratum in: J Clin Oncol 2008;26(19):3295
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357(20):2040-8
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, Eastern cooperative oncology group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646-54; Erratum in: J Clin Oncol 2006;24(4):724
   PubMed Web of Science ®Google Scholar
• Adams RA, Meade AM, Madi A, Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 2009;100(2):251-8
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L, Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28(6):911-17
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Nowacki M, Lang I, Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. [abstract 4000]. Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, Illinois
   Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A, Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. [abstract 4035]. Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, Illinois
   Google Scholar
• Hecht JR, Mitchell E, Chidiac T, A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27(5):672-80
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64
   PubMed Web of Science ®Google Scholar
• Siena S, Cassidy J, Tabernero J, Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. [abstract 283]. 2010 Gastrointestinal Cancers Symposium. January 22-24, 2010; Orlando, Florida
   Google Scholar
• Peeters M, Price TJ, Hotko YS, Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Patient-reported outcomes (PRO) [abstract 282]. 2010 Gastrointestinal Cancers Symposium. January 22-24, 2010; Orlando, Florida
   Google Scholar
• Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-4
   PubMed Web of Science ®Google Scholar
• Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 2006;6:152-6
   PubMed Web of Science ®Google Scholar
• Tejpar S, Piessevaux H, Claes K, Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007;8:387-94
   PubMed Web of Science ®Google Scholar
• Daugaard G, Strandgaard S, Holstein-Rathlou N-H, The renal handling of sodium and water is not affected by the standard-dose cisplatin treatment for testicular cancer. Scand J Clin Lab Invest 1987;47:455-9
   PubMed Web of Science ®Google Scholar
• Izzedine H, Rixe O, Billemont B, Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007;50:203-18
   PubMed Web of Science ®Google Scholar
• Nakopoulou L, Stefanaki K, Boletis J, Immunohistochemical study of epidermal growth factor receptor (EGFR) in various types of renal injury. Nephrol Dial Transplant 1994;9:764-9
   PubMed Web of Science ®Google Scholar
• Groenestege WM, Thebault S, Van Der Wijst J, Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007;117:2260-7
   PubMed Web of Science ®Google Scholar
• Hunter RJ, Pace MB, Burns KA, Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment. Support Care Cancer 2009;17(9):1195-201
   PubMed Web of Science ®Google Scholar
• Bodnar L, Wcislo G, Gasowska-Bodnar A, Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 2008;44(17):2608-14
   PubMed Web of Science ®Google Scholar
• Saif MW. Management of hypomagnesemia in cancer patients receiving chemotherapy. J Support Oncol 2008;6(5):243-8
   PubMedGoogle Scholar
• Hodgkinson E, Neville-Webbe HL, Coleman RE. Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol) 2006;18(9):710-18
   PubMed Web of Science ®Google Scholar
• Lofts FJ, Evans TR, Wastnage R, Mansi JL. Magnesium supplements with cisplatin chemotherapy. Eur J Cancer 1996;32A(3):556-7
   PubMed Web of Science ®Google Scholar
• Evans TR, Harper CL, Beveridge IG, A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer 1995;31A(2):174-8
   PubMed Web of Science ®Google Scholar
• Martin M, Diaz-Rubio E, Casado A, Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol 1992;15(4):348-51
   PubMed Web of Science ®Google Scholar
• Vokes EE, Mick R, Vogelzang NJ, A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia. Br J Cancer 1990;62(6):1015-17
   PubMed Web of Science ®Google Scholar
• Kibirige MS, Morris-Jones PH, Addison GM. Prevention of cisplatin-induced hypomagnesemia. Pediatr Hematol Oncol 1988;5(1):1-6
   PubMed Web of Science ®Google Scholar
• Willox JC, McAllister EJ, Sangster G, Kaye SB. Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 1986;54(1):19-23
   PubMed Web of Science ®Google Scholar
• Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979;90(6):929-31
   PubMed Web of Science ®Google Scholar
• Sgambato A, Wolf FI, Faraglia B, Cittadini A. Magnesium depletion causes growth inhibition, reduced expression of cyclin D1 and increased expression of p27kip1 in normal but not in transformed mammary epithelial cells. J Cell Physiol 1999;180:245-54
   PubMed Web of Science ®Google Scholar
• Wolf FI, Trapani V. Cell (Patho)physiology of Magnesium. Clin Sci 2008;114:27-35
   PubMed Web of Science ®Google Scholar
• Maier JAM, Nasulewicz-Goldeman A, Simonacci M, Insights into the mechanisms involved in magnesium-dependent inhibition of primary tumor growth. Nutr Cancer 2007;59:192-8
   PubMed Web of Science ®Google Scholar
• Maier JAM, Malpuech-Brugere C, Zimowska W, Low magnesium promotes endothelial dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta 2004;1689:13-24
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Santini D, Galluzzo S, Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res 2008;14:4219-24
   PubMed Web of Science ®Google Scholar
• Nasulewicz A, Wietrzyk J, Wolf FI, Magnesium deficiency inhibits primary tumor growth but favors metastasis in mice. Biochim Biophys Acta 2004;1739:26-32
   PubMed Web of Science ®Google Scholar
• Mazur A, Maier JAM, Rock E, Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys 2007;458:48-56
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49
   PubMed Web of Science ®Google Scholar
• Bernardini D, Nasulewicz A, Mazur A, Maier JAM. Magnesium and microvascular endothelial cells: a role in inflammation and angiogenesis. Front Biosci 2005;10:1177-82
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 2007;14:377-86
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Galluzzo S, Santini D, Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol 2011;22(5):1141-6
   PubMed Web of Science ®Google Scholar